Robert Arch, PhD, and Tomas Hode, PhD, will connect with the global interventional oncology community September 5–9.

Immunophotonics will attend the CIRSE 2026 Annual Congress, taking place September 5–9 in Copenhagen, Denmark. The congress is a major annual event for the interventional radiology community and has played an important role in helping Immunophotonics build relationships, establish clinical collaborations, and shape its clinical development strategy.

As the company enters an exciting new chapter, Immunophotonics remains focused on advancing IP-001 and generating the clinical data needed to explore its potential across multiple cancer indications. With ongoing Phase 2 trials, expanding clinical collaborations, and a strengthened financial foundation following the recent closing of the first $10 million in its Series C financing, the company looks forward to continuing its progress within the field of Interventional Immuno-Oncology®.

CEO Robert Arch, PhD, and co-founder Tomas Hode, PhD, will represent Immunophotonics at the congress. They welcome the opportunity to connect with investigators, physicians, partners, and innovators from across the global interventional oncology community.

Collaboration will continue to play an essential role in shaping the future of cancer therapy, and CIRSE provides an important forum for building the relationships that help move the field forward.